Controlled release of heparin-binding growth factors using heparin-containing particulate systems for tissue regeneration

Expert Opinion on Drug Delivery

Volumn 5, Issue 11, 2008, Pages 1173-1184

  Joung, Yoon Ki ^a   Bae, Jin Woo ^a   Park, Ki Dong ^a  

^a Ajou University   (South Korea)

Author keywords

Controlled release; Growth factor delivery; Heparin; Heparin binding growth factor (HBGF); Polymeric particulate; Tissue regeneration

Indexed keywords

ALGINIC ACID; BASIC FIBROBLAST GROWTH FACTOR; BONE MORPHOGENETIC PROTEIN; CHITOSAN; DEXAMETHASONE; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR; GELATIN; HEPARIN; MACROGOL; NANOCAPSULE; NERVE GROWTH FACTOR; PLACENTAL GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR; POLOXAMER; POLY(METHYL METHACRYLATE); POLYCAPROLACTONE; POLYETHYLENEIMINE; POLYGLACTIN; POLYLYSINE; POLYMACON; POLYMER; RECOMBINANT VASCULOTROPIN; SCATTER FACTOR; SOMATOMEDIN; SOMATOMEDIN C; TRANSFORMING GROWTH FACTOR; TRANSFORMING GROWTH FACTOR BETA1; UNINDEXED DRUG; VASCULOTROPIN;

ALZHEIMER DISEASE; ANGIOGENESIS; BONE REGENERATION; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; DIABETES MELLITUS; DRUG DELIVERY SYSTEM; DRUG MECHANISM; DRUG POTENTIATION; ENCAPSULATION; ERECTILE DYSFUNCTION; FEMUR FRACTURE; GENE THERAPY; HUMAN; HYDROGEL; NERVE REGENERATION; NONHUMAN; PARKINSON DISEASE; REVIEW; SPINAL CORD INJURY; TIBIA FRACTURE; TISSUE ENGINEERING; TISSUE REGENERATION; WOUND HEALING;

ANIMALS; ANTICOAGULANTS; CARBOHYDRATE SEQUENCE; DELAYED-ACTION PREPARATIONS; DRUG DELIVERY SYSTEMS; FIBROBLAST GROWTH FACTOR 2; HEPARIN; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MOLECULAR SEQUENCE DATA; NERVE GROWTH FACTOR; REGENERATION; TRANSFORMING GROWTH FACTOR BETA1; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 57049189799     PISSN: 17425247     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425240802431811     Document Type: Review

References (98)

1. McKay IA. Growth factors: a practical approach. IRL Press: Oxford; 1993
2. Boontheekul T, Mooney DJ. Protein-based signaling systems in tissue engineering. Curr Opin Biotech 2003;14:559-65
3. Iwaniec UT, Magee KA, Mitova-Caneva NG, et al. Bone anabolic effects of subcutaneous treatment with basic fibroblast growth factor alone and in combination with estrogen in osteopenic ovariectomized rats. Bone 2003;33:380-38
4. Tao Y, Black IB, Dicicco-Bloom E. Neurogenesis in neuronatal rat brain is regulated by peripheral injection of basic fibroblast growth factor (bFGF). J Comp Neurol 1996;376:653-63
5. Schifitto G, Yiannoutsos C, Simpson DM, et al. Long-term treatment with recombinant nerve growth factor for HIV-associated sensory neuropathy. Neurology 2001;57:1313-6
6. Ueda Y, Yamagishi T, Ikeya H, et al. A novel binding antagonist of VEGF, inhibits angiogenesis in vitro and in vivo. Anticancer Res 2004;24:3009-17
7. Rosen LS. Clinical experience with angiogenesis signaling inhibitors: focus on vascular endothelial growth factor (VEGF) blockers. Cancer Control 2002;9:36-44
8. Byrne AM, Bouchier-Hayes DJ, Harmey JH. Angiogenic and cell survival functions of vascular endothelial growth factor (VEGF). J Cell Mol Med 2005;9:777-94
9. Capila I, Linhardt RJ. Heparin - protein interactions. Angew Chem Int Ed 2002;41:390-412
10. Baldwin SP, Saltzman WM. Materials for protein delivery in tissue engineering. Adv Drug Deliv Rev 1998;33:71-86
11. Hock JM, Canalis E, Centrella M. Transforming growth factor-beta stimulates bone matrix apposition and bone cell replication in cultured fetal rat calvariae. Endocrinology 1990;126:421-6
12. Joyce M, Roberts A, Sporn M, et al. Transforming growth factor-β and the initiation of chondrogenesis and osteogenesis in the rat femur. J Cell Biol 1990;110:2195-207
13. Lu L, Stamatas GN, Mikos AG. Controlled release of transforming growth factor from biodegradable polymer microparticles. J Biomed Mater Res 2000;50:440-51
14. Peter SJ, Lu L, Kim DJ, et al. Effects of transforming growth factor 1 released from biodegradable polymer microparticles on marrow stromal osteoblasts cultured on poly(propylene fumarate) substrates. J Biomed Mater Res 2000;50:452-62
15. Cleek RL, Rege AA, Denner LA, et al. Inhibition of smooth muscle cell growth in vitro by an antisense oligodeoxynucleotide released from poly(DL-lactic-co-glycolic acid) microparticles. J Biomed Mater Res 1997;35:525-30
16. Dailey L, Ambrosetti D, Mansukhani A, et a. Mechanisms underlying differential responses to FGF signaling. Cytokine Growth Factor Rev 2005;16:233-47
17. Perets A, Baruch Y, Weisbuch F, et al. Enhancing the vascularization of thee-dimensional porous alginate scaffolds by incorporating controlled release basic fibroblast growth factor microspheres. J Biomed Mater Res A 2003;65A:489-97
18. Suetomi T, Hisasue SI, Sato Y, et al. Effect of basic fibroblast growth factor incorporating cleatin microspheres on erectile function in the diabetic rat. J Urol 2005;173:1423-8
19. Rogers RS, Graziottin TM, Lin CS, et al. Intracavernosal vascular endothelial growth factor (VEGF) injection and adeno-associated virus-mediated VEGF gene therapy prevent and reverse venogenic erectile dysfunction in rats. Int J Impot Res 2003;15:26-37
20. Dai Q, Silverstein AD, Davies MG, et al. Systemic basic fibroblast growth factor induces favorable histological changes in the corpus cavernosum of hypercholesterolemic rabbits. J Urol 2003;170:664-8
21. Bochinski D, Hsieh PS, Nunes L, et al. Effect of insulin-like growth factor-1 and insulin-like growth factor binding protein-3 complex in cavernous nerve cryoablation. Int J Impot Res 2004;16:418-23
22. Ferrara N. Role of vascular endothelial growth factor in regulation of physiological angiogenesis. Am J Physiol Cell Physiol 2001;280:c1358-66
23. Zelzer E, McLean W, Ng YS, et al. Skeletal defects in VEGF(120/120) mice reveal multiple roles for VEGF in skeletogenesis. Development 2002;129(8):1893-904
24. Sondell M, Lundborg G, Kanje M. Vascular endothelial growth factor has neurotrophic activity and stimulates axonal outgrowth, enhancing cell survival and Schwann cell proliferation in the peripheral nervous system. J Neurosci 1999;19:5731-40
25. Oberg-Welsh C, Sandler S, Andersson A, et al. Effects of vascular endothelial growth factor on pancreatic duct cell replication and the insulin production of fetal islet-like cell clusters in vitro. Mol Cell Endocrinol 1997;126:125-32
26. Banai S, Jaklitsch MT, Shou M, et al. Angiogenic-induced enhancement of collateral blood flow to ischemic myocardium by vascular endothelial growth factor in dogs. Circulation 1994;89:2183-9
27. Pearlman JD, Hibberd MG, Chuang ML, et al. Magnetic resonance mapping demonstrate benefits of VEGF induced myocardial angiogenesis. Nat Med 1995;1:1085-9
28. Harada K, Friedman M, Lopez JJ, et al. Vascular endothelial growth factor administration in chronic myocardial ischemia. Am J Physiol 1996;270:1791-802
29. Lee RJ, Springer ML, Blanco-Bose WE, et al. VEGF gene delivery to myocardium: deleterious effects of unregulated expression. Circulation 2000;102:898-901
30. King TW, Patrick CW Jr. Development and in vitro characterization of vascular endothelial growth factor (VEGF)-loaded poly(D,L-lactic-co-glycolic acid)/poly(ethylene glycol) microspheres using a solid encapsulation/single emulsion/solvent extraction technique. J Biomed Mater Res 2000;51:383-90
31. Cleland JL, Duenas ET, Park A, et al. Development of poly(D,L-lactide-coglycolide) microsphere formulations containing recombinant human vascular endothelial growth factor to promote local angiogenesis. J Control Release 2001;72:13-24
32. Faranesh AZ, Nastley MT, Cruz CPD, et al. Theoretical and experimental investigation of the VASO contrast mechanism. Magn Reson Med 2004;51:1265-73
33. Norton LW, Tegnella E, Toporekb SS, et al. In vitro characterization of vascular endothelial growth factor and dexamethasone releasing hydrogels for implantable probe coatings. Biomaterials 2005;26:3285-97
34. Conn G, Soderman DD, Schaeffer MT, et al. Purification of a glycoprotein vascular endothelial cell mitogen from a rat glioma-derived cell line. Proc Natl Acad Sci USA 1990;87:1323-7
35. Nissen NN, Polverini PJ, Koch AE, et al. Vascular endothelial growth factor mediates angiogenic activity during the proliferative. phase of wound healing. Am J Pathol 1998;152:1445-52
36. Shibayama E, Koizumi H. Cellular localization of the trk neurotrophin receptor family in human non-neuronal tissues. Am J Pathol 1996;148:1807-18
37. Camarata PJ, Suryanarayanan R, Turner DA, et al. Sustained release of nerve growth factor from biodegradable polymer microspheres. Neurosurgery 1992;30:313-9
38. Mittal S, Cohen A, Maysinger D. In vitro effects of brain derived neurotrophic factor released from microspheres. Neuroreport 1994;5:2577-82
39. Krewson CE, Dause R, Mak M, et al. Stabilization of nerve growth factor in controlled release polymers and in tissue. J Biomater Sci Polym Ed 1996;8:103-17
40. Péan JM, Menei P, Morel O, et al. Intraseptal implantation of NGF-releasing microspheres promotes the survival of axotomized cholinergic neurons. Biomaterials 2000;21:2097-101
41. Montero CN, Hefti F. Rescue of lesioned septal cholinergic neurons by nerve growth factor: specificity and requirement for chronic treatment. J Neurosci 1998;8:2986-99
42. Tatard VM, Venier-Julienne MC, Saulnier P, et al. Pharmacologically active microcarriers: a tool for cell therapy. Biomaterials 2005;26:3727-37
43. Cao X, Shoichet MS. Delivering neuroactive molecules from biodegradable microspheres for application in central nervous system disorders. Biomaterials 1999;20:329-39
44. Piotrowicza A, Shoichet MS. Nerve guidance channels as drug delivery vehicles. Biomaterials 2006;27:2018-27
45. Xu X, Yu H, Gao S, et al. Polyphosphoester microspheres for sustained release of biologically active nerve growth factor. Biomaterials 2002;23:3765-72
46. Xu X, Yee WC, Hwang PYK, et al. Peripheral nerve regeneration with sustained release of poly(phosphoester) microencapsulated nerve growth factor within nerve guide conduits. Biomaterials 2003;24:2405-12
47. Wang S, Wan AC, Xu X, et al. A new nerve guide conduit material composed of a biodegradable poly(phosphoester). Biomaterials 2001;22:1157-69
48. Jee KS, Park HD, Park KD, et al. Heparin conjugated polylactide as a blood compatible materials. Biomacromolecules 2004;5:1877-81
49. Go DH, Joung YK, Park SY, et al. Heparin-conjugated star-shaped PLA for improved biocompatibility. J Biomed Mater Res A 2008;86A:842-8
50. Jeon O, Kang SW, Lim HW, et al. Long-term and zero-order release of basic fibroblast growth factor from heparin-conjugated poly(L-lactide-co-glycolide) nanospheres and fibrin gel. Biomaterials 2006;27:1598-607
51. Kim SK, Lee EH, Vaishali B, et al. Tricaprylin microemulsion for oral delivery of low molecular weight heparin conjugates. J Control Release 2005;105:32-42
52. Moon HT, Lee YK, Han JK, et al. A novel formulation for controlled release of heparin-DOCA conjugate dispersed as nanoparticles in polyurethane film. Biomaterials 2001;22:281-9
53. Lee DY, Kim SK, Kim YS, et al. Suppression of angiogenesis and tumor growth by orally active deoxycholic acid-heparin conjugate. J Control Release 2007;118:310-7
54. Lee JS, Go DH, Bae JW, et al. Synthesis and characterization of heparin conjugated Tetronic-PCL copolymer for protein drug delivery. Curr Appl Phys 2007;7(Suppl 1):e49-e52
55. Lee JS, Go DH, Bae JW, et al. Heparin conjugated polymeric micelle for long-term delivery of basic fibroblast growth factor. J Control Release 2007;117:204-9
56. Lee JS, Bae JW, Joung YK, et al. Controlled dual release of basic fibroblast growth factor and indomethacin from heparin-conjugated polymeric micelle. Int J Pharm 2008;346:57-63
57. Choi SH, Lee JH, Choi SM, et al. Thermally reversible Pluronic/heparin nanocapsules exhibiting 1000-fold volume transition. Langmuir 2006;22:1758-62
58. Qiu GM, Xu YY, Zhu BK, et al. Novel, fluorescent, magnetic, polysaccharide-based microsphere for orientation, tracing, and anticoagulation: preparation and characterization. Biomacromolecules 2005;6:1041-7
59. Passirani C, Barratt G, Devissaguet JP, et al. Interactions of nanoparticles bearing heparin or dextran covalently bound to poly (methyl methacrylate) with the complement system. Life Sci 1998;62:775-85
60. Chung YI, Tae G, Yuk SH. A facile method to prepare heparin-functionalized nanoparticles for controlled release of growth factors. Biomaterials 2006;27:2621-6
61. Sahli A, Cansell M, Tapon-Bretaudiéte J, et al. The stability of heparin-coated liposomes in plasma and their effect on its coagulation. Colloids Surf B 1998;10:205-15
62. Na K, Kim SW, Park KS, et al. Heparin/poly(l-lysine) nanoparticle-coated polymeric microspheres for stem-cell therapy. J Am Chem Soc 2007;129:5788-9
63. Chinen N, Tanihara M, Nakagawa M, et al. Action of microparticles of heparin and alginare crosslinked gel when used as injectable artificial matrices to stabilize basic fibroblast growth factor and induce angiogenesis by controlling its release. J Biomed Mater Res 2003;67A:61-8
64. Andersson M, Loroth JE. Small particles of a heparin/chitosan complex prepared from a pharmaceutically acceptable microemulsion. Int J Pharm 2003;257:305-9
65. Rajangam K, Behanna HA, Hui MJ, et al. Heparin binding nanostructures to promote growth of blood vessels. Nano Lett 2006;6(9):2086-90
66. Thompson LD, Pantoliano MW, Springer BA. Energetic characterization of the basic fibroblast growth factor-heparin interaction: identification of the heparin binding domain. Biochemistry 1994;33:3831-40
67. Freire E, Mayorga OL, Straume M. Isothermal titration calorimetry. Anal Chem 1990;62:A950-9
68. Mach H, Volkin DB, Burke CJ, et al. Nature of the interaction of heparin with acidic fibroblast growth factor. Biochemistry 1993;32:5480-9
69. Gitay-Goren H, Soker S, Vladovsky I, et al. The binding of vascular endothelial growth factor to its receptors is dependent on cell surface-associated heparin-like molecules. J Biol Chem 1992;267:6093-8
70. Bussolino F, DiRenzo MF, Ziche M, et al. Hepatocyte growth. factor is a potent angiogenic factor which stimulates endothelial cell motility and growth. J Cell Biol 1992;119:629-41
71. Naka D, Ishii T, Shimomura T, et al. Heparin modulates the receptor-binding and mitogenic activity of hepatocyte growth factor on hepatocytes. Exp Cell Res 1993;209:317-24
72. Palladino MA, Morris RE, Starnes HF, et al. The transforming growth factor-beta. A new family of immunoregulatory molecules. Ann NY Acad Sci 1990;593:181-7
73. McCaffrey TA, Falcone DJ, Du B. Transforming growth factor-beta 1 is a heparin-binding protein: identification of putative heparin-binding regions and isolation of heparins with varying affinity for TGF-beta 1. J Cell Physiol 1992;152:430-40
74. Thompson SA, Higashiyama S, Wood K, et al. Characterization of sequences within heparin-binding EGF-like growth factor that mediate interaction with heparin. J Biol Chem 1994;269:2541-9
75. Feyzi E, Lustig F, Fager G, et al. Characterization of heparin and heparan sulfate domains binding to the long splice variant of platelet-derived growth factor A chain. J Biol Chem 1997;272:5518-24
76. Langer R. Drug delivery systems. XVI(9). MRS Bull; 1991
77. Kabanova AV, Batrakova EV, Alakhov VY. Pluronic® block copolymers as novel polymer therapeutics for drug and gene delivery. J Control Release 2002;82:189-212
78. Malmsten M. Surfactants and polymers in: drug delivery. New York: Elsevier; 2000
79. Moghimi SM, Hunter AC. Poloxamers and poloxamines in nanoparticle engineering and experimental medicine. Trends Biotechnol 2000;18:412-20
80. Kabanov AV, Alakhov VY. Amphiphilic block copolymers: self-assembly and applications. New York: Elsevier; 2000
81. Matthew JE, Nazario YL, Roberts SC, et al. Effect of mammalian cell culture medium on the gelation properties of Pluronic® F127. Biomaterials 2002;23:4615-9
82. Wang W. Instability, stabilization, and formulation of liquid protein pharmaceuticals. Int J Pharm 1999;185:129-88
83. Nimni ME. Polypeptide growth factors: targeted delivery systems. Biomaterials 1997;18:1201-25
84. Salvay DM, Shea LD. Inductive tissue engineering with protein and DNA-releasing scaffolds. Mol Biosyst 2006;2:36-48
85. Cho TJ, Gerstenfeld LC, Einhorn TA. Differential temporal expression of members of the transforming growth factor beta superfamily during murine fracture healing. J Bone Miner Res 2002;17:513-20
86. Richardson TP, Peters MC, Ennett AB, et al. Polymeric system for dual growth factor delivery. Nat Biotechnol 2001;19:1029-34
87. Schmidmaier G, Wildemann B, Gabelein T, et al. Synergistic effect of IGF-I and TGF β1 on: fracture healing in rats single versus combined application of IGF-I and TGF β1. Acta Orthop Scand 2003;74:604-10
88. Simmons CA, Alsberg E, Hsiong S, et al. Dual growth factor delivery and controlled scaffold degradation enhance in vivo bone formation by transplanted bone marrow stromal cells. Bone 2004;35:562-9
89. Vonau RL, Bostrom MP, Aspenberg P, et al. Combination of growth factors inhibits bone ingrowth in the bone harvest chamber. Clin Orthop 2001;386:243-51
90. Song S, Ewald AJ, Stallcup W, et al. PDGFR beta + perivascular progenitor cells in tumors regulate pericyte differentiation and vascular survival. Nat Cell Biol 2005;7:870-9
91. Terenghi G. Peripheral nerve regeneration and neurotrophic factors. J Anat 1999;194:1-14
92. Ahmed Z, Brown RA, Ljungberg C, et al. Nerve growth factor enhances peripheral nerve regeneration in non-human primates. Scand J Plast Reconstr Hand Surg 1999;33:393-401
93. Piotrowicz A, Shoichet MS. Nerve guidance channels as drug delivery vehicles. Biomaterials 2006;27:2018-27
94. Petitou M, Hérault JP, Bernat A, et al. Synthesis of thrombin-inhibiting heparin mimetics without side effects. Nature 1999;398:417-22
95. Parsons CL. Ephthelial coating techniques in the treatment of interstitial cystitis. Urology 1997;49:100-4
96. Fryer A, Huang YC, Rao G, et al. Selective O-desulphation produces non-anticoagulant heparin that retains pharmacologic activity in the lung. J Pharmacol Exp Ther 1997;282:209-19
97. McLeskey SW, Zhang L, Trock BJ, et al. Effects of AGM-1470 and pentosan polysulphate on tumorigenicity and metastasis of FGF-transfected MCF-7 cells. Br J Cancer 1996;73:1053-62
98. Gotkin B, Mendoza-Ayala R, Campo C, et al. Effect of heparin tetrasaccharide on late phase responses in ovine and murine models of asthma: comparison with budesonide. Am J Respir Crit Care Med 1999;159:A874